Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...

The University of Iowa study is analyzing the period between breast cancer diagnosis and treatment, when many patients feel ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of ...

Triple negative breast cancer wreaks a particularly heavy toll in certain regions and populations, with stark differences in both incidence and survival rates ...

Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks ...